Explore

Mayim Bialik's Experience with GLP-1 Medication Highlights Severe Side Effects

Mayim Bialik's Experience with GLP-1 Medication Highlights Severe Side Effects

Mayim Bialik's Experience with GLP-1 Medication Highlights Severe Side Effects

Mayim Bialik Reveals Severe Side Effects from GLP-1 Medication, Calls Experience a 'Nightmare'

Mayim Bialik Reveals Severe Side Effects from GLP-1 Medication, Calls Experience a 'Nightmare'

Mayim Bialik Reveals Severe Side Effects from GLP-1 Medication, Calls Experience a 'Nightmare'

FDA Warnings Highlight Risks of Mounjaro for Type 2 Diabetes Patients

FDA Warnings Highlight Risks of Mounjaro for Type 2 Diabetes Patients

Mounjaro, a prescription drug containing tirzepatide, was approved by the FDA in 2022 for treating adults with Type 2 diabetes. It functions by targeting two hormone receptors, GIP and GLP-1, to lower blood sugar and curb appetite, often resulting in weight loss. Despite its effectiveness, Mounjaro has been associated with several gastrointestinal side effects, including nausea, vomiting, and diarrhea. More severe complications such as stomach paralysis, pancreatitis, and acute kidney injury have also been reported. The FDA has issued a black box warning for the risk of thyroid C-cell tumors based on animal studies. Additionally, lawsuits have been filed claiming that Mounjaro causes serious gastrointestinal issues, including stomach paralysis.

GLP-1 Weight-Loss Drugs Linked to Lower Breast Cancer Risk in New Study

GLP-1 Weight-Loss Drugs Linked to Lower Breast Cancer Risk in New Study

Recent research presented at the 2026 American Society of Clinical Oncology Annual Meeting suggests that GLP-1 weight-loss drugs, including Ozempic and Wegovy, may reduce the risk of breast cancer by approximately 30%. The study involved over 110,000 women and found that those taking these medications had a significantly lower likelihood of developing breast cancer compared to those who did not. The research, led by Dr. Elizabeth McDonald from the University of Pennsylvania, highlights the potential of these drugs as cancer prevention tools, although it remains observational and does not establish a direct causal relationship. The study reviewed health records of women aged 45 to 80 with a BMI of 25 or higher, revealing consistent results across different analyses.

GLP-1 Weight Loss Drugs Linked to Reduced Breast Cancer Risk

GLP-1 Weight Loss Drugs Linked to Reduced Breast Cancer Risk

Recent observational studies have found that GLP-1 drugs, commonly used for weight loss and diabetes management, may also reduce the risk of breast cancer. The studies, presented at the American Society of Clinical Oncology's annual meeting, indicate that women taking these medications have a 30% lower chance of developing breast cancer. Additionally, those diagnosed with breast cancer while on GLP-1 drugs are less likely to experience disease progression or mortality. The research, led by Elizabeth McDonald from the University of Pennsylvania, analyzed health data from over 110,000 women and suggests that these drugs could serve as potential cancer prevention tools.

Study Links GLP-1 Weight-Loss Drugs to Reduced Breast Cancer Risk

Study Links GLP-1 Weight-Loss Drugs to Reduced Breast Cancer Risk

Recent research presented at the 2026 American Society of Clinical Oncology Annual Meeting suggests that GLP-1 weight-loss drugs, including Ozempic and Wegovy, may reduce the risk of breast cancer by approximately 30%. The study involved over 110,000 women and found that those taking these medications were significantly less likely to develop breast cancer compared to those who were not. The findings, while observational, add to a growing body of evidence that these drugs could serve as potential cancer prevention tools. Researchers are planning a multisite clinical trial to further investigate this potential benefit.

GLP-1 Treatment Discontinuation Raises Weight Regain Fears Among Midlife Women

GLP-1 Treatment Discontinuation Raises Weight Regain Fears Among Midlife Women

GLP-1 drugs, such as Wegovy and Ozempic, are widely used by midlife women for weight management and type 2 diabetes treatment. However, discontinuing these medications often leads to weight regain, causing significant anxiety among users. Dr. Jessica Shepherd, a board-certified OB-GYN, highlights that weight loss through GLP-1s often improves health and confidence, making the prospect of regaining weight distressing. Dr. Rebecca G. Boswell, a clinical psychologist, notes that many women using these drugs have histories of yo-yo dieting and body dysmorphia, exacerbating fears of weight regain. The resurgence of a thin-ideal in cultural narratives further complicates women's relationships with their bodies. Experts recommend thorough screening for eating disorders when prescribing GLP-1s and emphasize the importance of a multidisciplinary approach to weight management.

Serena Williams' Endorsement of GLP-1 Drugs Highlights Growing Trend in Fitness and Longevity

Serena Williams' Endorsement of GLP-1 Drugs Highlights Growing Trend in Fitness and Longevity

Serena Williams' Endorsement of GLP-1 Drugs Highlights Growing Trend in Fitness and Longevity

FDA and DOJ Actions Reshape Peptide Industry, Impacting Grey-Market Vendors

FDA and DOJ Actions Reshape Peptide Industry, Impacting Grey-Market Vendors

FDA and DOJ Actions Reshape Peptide Industry, Impacting Grey-Market Vendors

Mayim Bialik went on a GLP-1. It was a 'nightmare'

Mayim Bialik went on a GLP-1. It was a 'nightmare'

Mayim Bialik said she experienced nightmare side effects on a GLP-1. Here's what happened.

Aurinia Pharmaceuticals Reports Significant Risk Reduction with LUPKYNIS in Lupus Nephritis

Aurinia Pharmaceuticals Reports Significant Risk Reduction with LUPKYNIS in Lupus Nephritis

Aurinia Pharmaceuticals Reports Significant Risk Reduction with LUPKYNIS in Lupus Nephritis

Viral cookie chain files Chapter 11 bankruptcy

Viral cookie chain files Chapter 11 bankruptcy

Viral baked goods, even ones from a company named "Best Cookie Shop" by USA Today, have proven to be a challenging business. Crumbl Cookies, the unquestioned leader in the cookie cafe space, has struggled after a period of explosive growth. In addition, Taylor Chip, a cookie brand that operates ...